4 D Molecular Therapeutics Inc announced it raised $90 Million in an initial filing from an offering of $90 Million

Company

Location

About

4DMT is a late-stage biotechnology company developing durable, disease-targeted genetic medicines designed to transform treatment paradigms and deliver long-lasting benefits to patients. Its lead candidate, 4D-150, aims to become a backbone therapy for blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF agents through a single intravitreal injection, with Phase 3 development underway for wet age-related macular degeneration and a second indication in diabetic macular edema. The company’s second candidate, 4D-710, is the first known genetic medicine to achieve successful aerosol-based delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis.